FMR LLC - 15 Jan 2026 Form 4 Insider Report for Structure Therapeutics Inc. (GPCR)

Reporting relationship: Other*, 10%+ Owner
Issuer ticker: GPCR
Reported as of: 15 Jan 2026
Net transaction value: -$1,453,753
SEC form: 4
Accepted by SEC: 20 Jan 2026, 09:22:14 UTC
Prior SEC filing: 10 Dec 2025
Next SEC filing: 10 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson

Key filing fact

FMR LLC filed Form 4 for Structure Therapeutics Inc. (GPCR) on 20 Jan 2026.

Key facts

This page summarizes FMR LLC's Form 4 filing for Structure Therapeutics Inc. (GPCR).
8 reported transactions and 9 derivative rows are listed below.
Accepted by SEC: 20 Jan 2026, 09:22.

Change

Previous filing in this sequence was filed on 10 Dec 2025.
Current net transaction value: -$1,453,753.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0000315066 Primary reporting owner

FMR LLC

Relationship: Other*, 10%+ Owner
Address: 245 SUMMER STREET, BOSTON
Signature: /s/ Stephanie J. Brown, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
Signature date: 20 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GPCR holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 20,502
Date: 15 Jan 2026
Ownership: F-Prime Capital Partners Life Sciences Advisors Fund VI LP

GPCR holding

Ordinary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 241,275
Date: 15 Jan 2026
Ownership: F-Prime Capital Partners Life Sciences Fund VI LP

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GPCR transaction Derivative

American Depositary Shares

Sale

Transaction value: $38,176
Shares: -465
Change %: -8.5%
Price: $82.10
Shares after: 5,005
Date: 15 Jan 2026
Ownership: F-Prime Capital Partners Life Sciences Advisors Fund VI LP
Underlying class: Ordinary Shares
Underlying amount: 1,395
Exercise price
Footnotes: F1, F2

GPCR transaction Derivative

American Depositary Shares

Sale

Transaction value: $27,506
Shares: -330
Change %: -6.6%
Price: $83.35
Shares after: 4,675
Date: 15 Jan 2026
Ownership: F-Prime Capital Partners Life Sciences Advisors Fund VI LP
Underlying class: Ordinary Shares
Underlying amount: 990
Exercise price
Footnotes: F1, F3

GPCR transaction Derivative

American Depositary Shares

Sale

Transaction value: $46,489
Shares: -552
Change %: -12%
Price: $84.22
Shares after: 4,123
Date: 15 Jan 2026
Ownership: F-Prime Capital Partners Life Sciences Advisors Fund VI LP
Underlying class: Ordinary Shares
Underlying amount: 1,656
Exercise price
Footnotes: F1, F4

GPCR transaction Derivative

American Depositary Shares

Sale

Transaction value: $1,701
Shares: -20
Change %: -0.49%
Price: $85.04
Shares after: 4,103
Date: 15 Jan 2026
Ownership: F-Prime Capital Partners Life Sciences Advisors Fund VI LP
Underlying class: Ordinary Shares
Underlying amount: 60
Exercise price
Footnotes: F1, F5

GPCR transaction Derivative

American Depositary Shares

Sale

Transaction value: $449,662
Shares: -5,477
Change %: -8.5%
Price: $82.10
Shares after: 58,864
Date: 15 Jan 2026
Ownership: F-Prime Capital Partners Life Sciences Fund VI LP LP
Underlying class: Ordinary Shares
Underlying amount: 16,431
Exercise price
Footnotes: F1, F2

GPCR transaction Derivative

American Depositary Shares

Sale

Transaction value: $323,398
Shares: -3,880
Change %: -6.6%
Price: $83.35
Shares after: 54,984
Date: 15 Jan 2026
Ownership: F-Prime Capital Partners Life Sciences Fund VI LP
Underlying class: Ordinary Shares
Underlying amount: 11,640
Exercise price
Footnotes: F1, F3

GPCR transaction Derivative

American Depositary Shares

Sale

Transaction value: $547,262
Shares: -6,498
Change %: -12%
Price: $84.22
Shares after: 48,486
Date: 15 Jan 2026
Ownership: F-Prime Capital Partners Life Sciences Fund VI LP
Underlying class: Ordinary Shares
Underlying amount: 19,494
Exercise price
Footnotes: F1, F4

GPCR transaction Derivative

American Depositary Shares

Sale

Transaction value: $19,559
Shares: -230
Change %: -0.47%
Price: $85.04
Shares after: 48,256
Date: 15 Jan 2026
Ownership: F-Prime Capital Partners Life Sciences Fund VI LP
Underlying class: Ordinary Shares
Underlying amount: 690
Exercise price
Footnotes: F1, F5

GPCR holding Derivative

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,515,558
Date: 15 Jan 2026
Ownership: Shares held by persons and entities whose shares are subject to reporting by the undersigned
Underlying class: Ordinary Shares
Underlying amount: 4,546,674
Exercise price
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer.

Footnote F2

The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $82.00 to $82.37. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information

Footnote F3

The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $83.00 to $83.84. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information

Footnote F4

The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $84.00 to $84.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information

Footnote F5

The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $85.02 to $85.06. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information

SEC remarks

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: F-Prime Capital Partners Life Sciences Advisors Fund VI LP (FPCPLSA) is the general partner of F-Prime Capital Partners Life Sciences Fund VI LP. FPCPLSA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.